- Home
- ASTH vs JANX Comparison
ASTH vs JANX Comparison
Compare ASTH & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASTH
- JANX
- Stock Information
- Founded
- ASTH 1994
- JANX 2017
- Country
- ASTH United States
- JANX United States
- Employees
- ASTH N/A
- JANX N/A
- Industry
- ASTH Professional Services
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- ASTH Consumer Discretionary
- JANX Health Care
- Exchange
- ASTH Nasdaq
- JANX Nasdaq
- Market Cap
- ASTH 1.7B
- JANX 1.6B
- IPO Year
- ASTH N/A
- JANX 2021
- Fundamental
- Price
- ASTH $29.71
- JANX $25.56
- Analyst Decision
- ASTH Strong Buy
- JANX Strong Buy
- Analyst Count
- ASTH 8
- JANX 7
- Target Price
- ASTH $53.29
- JANX $94.29
- AVG Volume (30 Days)
- ASTH 234.4K
- JANX 929.3K
- Earning Date
- ASTH 05-08-2025
- JANX 05-08-2025
- Dividend Yield
- ASTH N/A
- JANX N/A
- EPS Growth
- ASTH N/A
- JANX N/A
- EPS
- ASTH 0.73
- JANX N/A
- Revenue
- ASTH $2,250,574,000.00
- JANX $9,336,000.00
- Revenue This Year
- ASTH $36.30
- JANX N/A
- Revenue Next Year
- ASTH $21.75
- JANX $250.58
- P/E Ratio
- ASTH $40.86
- JANX N/A
- Revenue Growth
- ASTH 54.81
- JANX 28.12
- 52 Week Low
- ASTH $23.12
- JANX $22.52
- 52 Week High
- ASTH $63.20
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- ASTH 41.89
- JANX 37.10
- Support Level
- ASTH $31.51
- JANX $24.13
- Resistance Level
- ASTH $33.67
- JANX $33.97
- Average True Range (ATR)
- ASTH 1.32
- JANX 2.01
- MACD
- ASTH -0.00
- JANX -0.61
- Stochastic Oscillator
- ASTH 11.41
- JANX 14.53
About ASTH Astrana Health Inc. Common Stock
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. Its operating segment is the healthcare delivery segment.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.